Skip to main content

Table 27 Risperidone for children and adolescents with anorexia nervosa

From: Canadian practice guidelines for the treatment of children and adolescents with eating disorders

Certainty assessment

Impact

Certainty

Importance

№ of studies

Study design

Risk of bias

Inconsistency

Indirectness

Imprecision

Other considerations

Weight (assessed with: kg), Psychological Symtpoms, Side Effects

 1

randomised trials

not serious

not serious

not serious

not serious

none

There were no significant differences in weight at end of study (risperidone n = 18, placebo n = 22). Even when just data from those under age 18 (placebo 18, risperidone 12) were analyzed separately, there were no differences. Mean dose 2.5 mg over 9 weeks.

HIGH

CRITICAL

not serious

not serious

not serious

not serious

none

There were no significant differences at end of study on any subscale of the EDI (Eating Disorders Inventory).

HIGH

CRITICAL

not serious

not serious

not serious

not serious

none

ECG, bloodwork (prolactin, lipids, liver enzymes, glucose) no differences. Patient in the treated group reported fatigue and dizziness.

HIGH

CRITICAL

Weight (assessed with: kg), Psychological Symptoms

 4

Case Reports

very serious a

not serious

not serious

serious a

none

Weight generally increased pre to post study period by several kg in 4 cases.

VERY LOW

CRITICAL

very serious a

not serious

not serious

serious a

none

Psychological symptoms including willingness to eat improved over the study period. Rigidity decreased. (n = 4)

VERY LOW

CRITICAL

  1. Explanations
  2. aThese are four case reports with no comparison condition
  3. Bibliography:
  4. RCT - Hagman 2011 [158]
  5. Case Reports - Fisman 1996 [159], Kracke 2014 [160], Umehara 2014 [161], Newman-Toker 2000 [162]